康方生物提交首份上市成绩单 首创双抗新药年内提交上市申请

证券日报网
01 Apr 2021

3月31日晚,港股公司康方生物(9926.HK)公布了上市后的首份年度成绩单。2020年报显示,2020年全年,康方生物实现其他收入净额约为1.235亿元(政府补助以及利息收入等);同期的研发投入达到7.645亿元。  目前,康方生物尚处在耕耘而非收获期。年报显示,2020年,康方生物共计40多个临床研究在全球高效推进中,其中9个研究处于注册性临床或III期临床阶段,4个注册性临床研究达到主要终点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10